BR112014011223A8 - Método de tratar uma doença proliferativa - Google Patents

Método de tratar uma doença proliferativa

Info

Publication number
BR112014011223A8
BR112014011223A8 BR112014011223A BR112014011223A BR112014011223A8 BR 112014011223 A8 BR112014011223 A8 BR 112014011223A8 BR 112014011223 A BR112014011223 A BR 112014011223A BR 112014011223 A BR112014011223 A BR 112014011223A BR 112014011223 A8 BR112014011223 A8 BR 112014011223A8
Authority
BR
Brazil
Prior art keywords
treatment
proliferative disease
serine
threonine kinase
kinase inhibitor
Prior art date
Application number
BR112014011223A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112014011223A2 (pt
Inventor
Stuart Darrin
Das Thakur Meghna
Original Assignee
Novartis Ag
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Array Biopharma Inc filed Critical Novartis Ag
Publication of BR112014011223A2 publication Critical patent/BR112014011223A2/pt
Publication of BR112014011223A8 publication Critical patent/BR112014011223A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112014011223A 2011-11-11 2012-11-09 Método de tratar uma doença proliferativa BR112014011223A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161558619P 2011-11-11 2011-11-11
PCT/US2012/064269 WO2013070996A1 (en) 2011-11-11 2012-11-09 Method of treating a proliferative disease

Publications (2)

Publication Number Publication Date
BR112014011223A2 BR112014011223A2 (pt) 2017-05-09
BR112014011223A8 true BR112014011223A8 (pt) 2023-01-31

Family

ID=47279036

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014011223A BR112014011223A8 (pt) 2011-11-11 2012-11-09 Método de tratar uma doença proliferativa

Country Status (10)

Country Link
US (1) US11007194B2 (enExample)
EP (1) EP2776037B1 (enExample)
JP (1) JP6150813B2 (enExample)
CN (2) CN103917236A (enExample)
AU (1) AU2012335663B2 (enExample)
BR (1) BR112014011223A8 (enExample)
CA (1) CA2855243C (enExample)
MX (1) MX354725B (enExample)
RU (1) RU2622015C2 (enExample)
WO (1) WO2013070996A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
EP3574904A1 (en) * 2012-08-07 2019-12-04 Array Biopharma, Inc. Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
CN109890386B (zh) 2016-06-03 2022-05-24 阵列生物制药公司 药物组合
WO2018107146A1 (en) * 2016-12-11 2018-06-14 Memorial Sloan Kettering Cancer Center Methods and compositions for treatment of braf mutant cancers
WO2020011141A1 (zh) * 2018-07-12 2020-01-16 深圳市塔吉瑞生物医药有限公司 一种二芳基吡唑化合物及包含该化合物的组合物及其用途
TWI817018B (zh) 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
IL294484A (en) * 2020-01-07 2022-09-01 Revolution Medicines Inc Shp2 inhibitor dosing and methods of treating cancer
PE20231651A1 (es) 2020-06-09 2023-10-17 Array Biopharma Inc Compuestos para el tratamiento de enfermedades y trastornos asociados a braf
CA3257280A1 (en) 2022-05-25 2023-11-30 Msd International Gmbh COMBINATION OF A BRAF INHIBITOR, AN EGFR INHIBITOR AND A PD-1 ANTAGONIST FOR THE TREATMENT OF COLORECTAL CANCER MSI-H/DMMR, WITH BRAF V600E MUTATION
ES3035530T3 (en) 2023-03-09 2025-09-04 Minneamrita Therapeutics Llc Drug combination for the treatment of stomach cancer
WO2025003956A1 (en) 2023-06-30 2025-01-02 Pfizer Inc. High drug loading formulations of encorafenib

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US6391636B1 (en) 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6037136A (en) 1994-10-24 2000-03-14 Cold Spring Harbor Laboratory Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
IL132991A (en) 1997-05-22 2005-11-20 Searle & Co Substituted pyrazoles, pharmaceutical compositionscomprising them and their use as p38 inase inhibi tors
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6204467B1 (en) 1998-03-24 2001-03-20 Ford Global Technologies, Inc. Method and apparatus for resistive welding
RU2319693C9 (ru) 1999-01-13 2008-08-20 Байер Копэрейшн Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты)
US6316435B2 (en) 1999-02-24 2001-11-13 Supergen, Inc. Combination therapy for lymphoproliferative diseases
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US20050043409A1 (en) 2001-10-25 2005-02-24 Chen Ying-Nan Pan Combinations comprising a selective cyclooxygenase-2 inhibitor
ATE374753T1 (de) 2001-12-21 2007-10-15 Vernalis Cambridge Ltd 3-(2,4)dihydroxyphenyl-4-phenylpyrazole und deren medizinische verwendung
BRPI0414698A (pt) 2003-09-23 2006-11-28 Novartis Ag combinação de um inibidor receptor de vegf com um agente quimioterapêutico
CA2545942C (en) 2003-11-14 2012-07-10 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
BRPI0506760A (pt) 2004-01-09 2007-05-22 Novartis Ag derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina como inibidores de igf-ir
RU2401265C2 (ru) 2004-06-10 2010-10-10 Айрм Ллк Соединения и композиции в качестве ингибиторов протеинкиназы
KR20070113295A (ko) 2005-03-17 2007-11-28 노파르티스 아게 티로신/트레오닌 키나제 억제제, 특히 ｂ-ｒａｆ 키나제억제제로서의ｎ-[3-(1-아미노-5,6,7,8-테트라히드로-2,4,4ｂ-트리아자플루오렌-9-일)-페닐]벤즈아미드
US20070099856A1 (en) * 2005-05-13 2007-05-03 Gumerlock Paul H Combined treatment with docetaxel and an epidermal growth factor receptor kinase inhibitor using an intermittent dosing regimen
AU2006279794B2 (en) 2005-08-12 2011-04-07 Synta Pharmaceuticals Corp. Pyrazole compounds that modulate HSP90 activity
AU2006284053B2 (en) 2005-08-22 2010-04-22 Novartis Ag Pharmaceutical compositions comprising a pH-dependent drug, a pH modifier and a retarding agent
US20080242667A1 (en) 2005-08-26 2008-10-02 Smithkline Beecham Corporation Pyrimidinyl-Pyrazole Inhibitors of Aurora Kinases
TWI387592B (zh) 2005-08-30 2013-03-01 Novartis Ag 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
JP2009530261A (ja) 2006-03-16 2009-08-27 ファイザー・プロダクツ・インク ピラゾール化合物
JP2009532497A (ja) 2006-04-05 2009-09-10 ノバルティス アクチエンゲゼルシャフト 癌を処置するための治療剤の組合せ
WO2007123892A2 (en) 2006-04-17 2007-11-01 Arqule Inc. Raf inhibitors and their uses
CA2663366C (en) 2006-10-02 2012-02-07 Irm Llc Compounds and compositions as protein kinase inhibitors
AU2007308045A1 (en) 2006-10-06 2008-04-17 Irm Llc Protein kinase inhibitors and methods for using thereof
WO2008100985A2 (en) 2007-02-15 2008-08-21 Novartis Ag Combination of lbh589 with other therapeutic agents for treating cancer
US20090022789A1 (en) 2007-07-18 2009-01-22 Supernus Pharmaceuticals, Inc. Enhanced formulations of lamotrigine
EA201000113A1 (ru) 2007-08-01 2010-08-30 Пфайзер Инк. Пиразольные соединения
AU2008313622A1 (en) 2007-10-19 2009-04-23 Abbott Gmbh & Co. Kg Solid dispersion product of N-aryl urea-based drugs
AU2008323287B2 (en) 2007-11-14 2011-07-14 Addex Pharma S.A. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US8129394B2 (en) 2008-03-21 2012-03-06 Novartis Ag Heteroaryl-substituted imidazole compounds and uses thereof
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
BRPI0916356B1 (pt) 2008-07-24 2022-08-23 Nerviano Medical Sciences S.R.L 3,4-diaril pirazois como inibidores da proteína quinase
MX2011001090A (es) 2008-07-28 2011-03-15 Gilead Sciences Inc Compuestos de inhibidor de desacetilasa de histona de cicloalquilideno y heterocicloalquilideno.
US8778929B2 (en) 2008-09-29 2014-07-15 Boehringer Ingelheim International Gmbh Substituted heteroaryl inhibitors of B-RAF
MY160340A (en) 2008-10-07 2017-02-28 Astrazeneca Uk Ltd Pharmaceutical formulation 514
US20110293750A1 (en) 2008-11-11 2011-12-01 Yale University Activated wnt-beta-catenin signaling in melanoma
US8524707B2 (en) 2008-12-19 2013-09-03 Nerviano Medical Sciences S.R.L. Bicyclic pyrazoles as protein kinase inhibitors
AR075180A1 (es) 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
RU2402602C1 (ru) 2009-02-12 2010-10-27 Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН КЛЕТОЧНАЯ ЛИНИЯ МЕЛАНОМЫ ЧЕЛОВЕКА mel Rac, ИСПОЛЬЗУЕМАЯ ДЛЯ ПОЛУЧЕНИЯ ПРОТИВООПУХОЛЕВЫХ ВАКЦИН
WO2010100127A1 (en) 2009-03-04 2010-09-10 Novartis Ag Disubstituted imidazole derivatives as modulators of raf kinase
TWI532484B (zh) 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
US8546413B2 (en) 2009-06-15 2013-10-01 Nerviano Medical Sciences S.R.L. Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors
KR101256018B1 (ko) 2009-08-20 2013-04-18 한국과학기술연구원 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
EA023942B1 (ru) 2010-01-27 2016-07-29 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Сульфонамидные производные 3,4-диарилпиразолов в качестве ингибиторов протеинкиназы
RU2639876C2 (ru) 2010-03-30 2017-12-25 Версеон Корпорейшн Мультизамещенные ароматические соединения в качестве ингибиторов тромбина
EP2601185B1 (en) 2010-08-03 2015-10-07 Nerviano Medical Sciences S.r.l. Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents
EP2688572B1 (en) 2011-03-21 2017-05-03 Valcuria AB A pharmaceutical composition comprising a hdac inhibitor and a steroid and the use thereof.
CA2844407A1 (en) 2011-06-14 2012-12-20 Novartis Ag Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm
KR102091295B1 (ko) 2011-11-23 2020-03-19 어레이 바이오파마 인크. 제약 제제
CA2890663A1 (en) 2012-11-08 2014-05-15 Novartis Ag Pharmaceutical combination comprising a b-raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases

Also Published As

Publication number Publication date
AU2012335663A1 (en) 2014-05-29
US20140275136A1 (en) 2014-09-18
JP2014533272A (ja) 2014-12-11
CA2855243A1 (en) 2013-05-16
CN103917236A (zh) 2014-07-09
US11007194B2 (en) 2021-05-18
CN108542906A (zh) 2018-09-18
RU2014117707A (ru) 2015-12-20
RU2622015C2 (ru) 2017-06-08
JP6150813B2 (ja) 2017-06-21
WO2013070996A1 (en) 2013-05-16
MX354725B (es) 2018-03-16
EP2776037B1 (en) 2019-01-09
EP2776037A1 (en) 2014-09-17
AU2012335663B2 (en) 2015-12-24
CA2855243C (en) 2020-04-14
HK1198920A1 (en) 2015-06-19
BR112014011223A2 (pt) 2017-05-09
MX2014005726A (es) 2014-05-28

Similar Documents

Publication Publication Date Title
BR112014011223A8 (pt) Método de tratar uma doença proliferativa
CR20140410A (es) Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento
ECSP14013329A (es) Compuestos de arylcarbonil-4-oxy-piperidina utilizados para el tratamiento de enfermedades neurodegenerativas
BR112016014410A2 (pt) terapia de combinação com vacina de neoantígeno
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
MX377157B (es) Preparación para usarse en el tratamiento de un cáncer positivo de gd2.
PH12014502048B1 (en) Treatment of cancer with tor kinase inhibitors
PH12014502046A1 (en) Treatment of cancer with tor kinase inhibitors
MX2014014839A (es) Terapias sinergicas de cannabidiol con hipotermia para neuroproteccion.
BR112016020260A8 (pt) uso de um composto na fabricação de um medicamento para tratar uma doença colestática intra-hepática
BR112015025719A2 (pt) terapia contra o câncer
CR20140473A (es) Compuestos de pirazol como inhibidores de sglt1
BR112015022825A2 (pt) métodos de diagnóstico, seleção e tratamento de doenças e condições causadas por ou associadas a metanógenos
MX2016000294A (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
BR112016012248A2 (pt) método de tratamento de nefropatia
PH12017500923A1 (en) New dosage and use of a a2a antagonist
IN2014KN01772A (enExample)
BR112015007095A2 (pt) derivados de di-hidro-6-azafenaleno para o tratamento de doenças do snc, oncológicas e distúrbios relacionados
MX375398B (es) Composición para la administración oral de magnesio en asociacion con una composicion para tratar la diabetes tipo 2 o las complicaciones de la misma.
EA201491939A1 (ru) Модуляторы прогестероновых рецепторов для применения в профилактике или лечении болезней, опосредованных андрогенами
UA89489U (ru) Способ лечения больных неалкогольным стеатогепатитом с коморбидным метаболическим синдромом
UY33411A (es) Uso de teriflunomida para el tratamiento de la atrofia cerebral
BR112013032188A2 (pt) composição, produto e método para tratar pacientes com hepatite c crônica
PL396438A1 (pl) Wykorzystanie melatoniny do wytwarzania leku do nowego zastosowania
UA69464U (uk) Спосіб лікування синдрому відміни кодтерпінової залежності у неповнолітніх

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25A Requested transfer of rights approved

Owner name: ARRAY BIOPHARMA INC. (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.